Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Extension of Indications for Durvalumab

New indication concerns first-line treatment of adults with extensive-stage small cell lung cancer
27 Jul 2020
Cancer Immunology and Immunotherapy;  Lung and other thoracic tumours

On 23 July 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product durvalumab (Imfinzi).

The marketing authorisation holder for this medicinal product is AstraZeneca AB.

The CHMP adopted an extension to the existing indication as follows (new text in bold):

  • IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy.
  • IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the European Commission decision, which will normally be issued 67 days from adoption of the opinion.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings